Navigation Links
China Nuvo Solar Energy, Inc. Completes Name Change to SurgLine International, Inc.
Date:1/26/2012

WEST PALM BEACH, Fla., Jan. 26, 2012 /PRNewswire/ -- China Nuvo Solar Energy, Inc., (OTCQB: CNUV) today announced the company's official name change to SurgLine International, Inc. has been completed and approved by FINRA. The Company will commence trading under the new OTC ticker symbol: SGLN, effective tomorrow, January 27, 2012. SurgLine, Inc. ("SurgLine") remains the wholly owned operating subsidiary of SGLN.

Thomas Toland, CEO of SGLN and SurgLine, stated, "We are very pleased that we have concluded being able to change the name of our public entity to SurgLine International, Inc., as it more accurately describes our core business of SurgLine. We also believe that it gives us the proper organizational structure to carry out not only our current plans, but our long term corporate strategy of building shareholder value."

About SurgLine, Inc.

SurgLine (www.surgline.com) sources and distributes high quality FDA approved medical and surgical products at discount prices, thereby reducing or eliminating the historical brand premium paid by healthcare providers including acute care hospitals, surgery centers, surgical hospital, self insured employers and insurance companies. SurgLine offers high quality medical and surgical supplies and products at substantial savings utilizing stocking distributors and institutional buyers by sourcing products globally without the historical brand premium and industry markup.

About SurgLine International, Inc.

SurgLine International, Inc. is a holding company that in addition to SurgLine, wholly owns Nuvo Solar Energy, Inc., a development stage company that owns unique patent pending solar and photovoltaic related technology.  The Company is also seeking other business opportunities.

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on the Company's current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements.

For Further Information Contact:
Thomas Toland
949-698-8485

 


'/>"/>
SOURCE China Nuvo Solar Energy, Inc.; SurgLine International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Sue Desmond-Hellmann, ... Class of 2016 to stretch the limits of human possibility in her keynote address ... p.m. in the Georgia Dome. , Drawing on her rich experience as a scientist, ...
(Date:5/3/2016)... ... , ... Calvary Hospital recently hosted a reception to mark a new music ... at Mary, Manning Walsh Home (MMW) in Manhattan. , During the school year, ... hour, once a week. The music brings a lot of joy to the patients, ...
(Date:5/3/2016)... NJ (PRWEB) , ... May 03, 2016 , ... ... BCBSNJ) today announced that it has been honored as one of the nation’s ... the 2016 InformationWeek Elite 100. Horizon received the recognition for technology achievements that ...
(Date:5/3/2016)... Springs, FL (PRWEB) , ... May 03, 2016 ... ... nation’s leading innovative specialty pharmacies, will be represented at the 2016 Asembia ... Las Vegas. The Asembia Summit is the largest U.S. health care conference for ...
(Date:5/3/2016)... ... May 03, 2016 , ... Empyrean ... launching a new client service center in La Vergne, Tennessee, near Nashville. The ... the full range of Empyrean client services. , “Our Nashville-area center allows us ...
Breaking Medicine News(10 mins):